Phio Pharmaceuticals Corp.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Phio Pharmaceuticals Corp. is a clinical-stage biotechnology firm focused on advancing immuno-oncology therapies within the United States. The company’s foundation rests upon its proprietary INTASYL™ platform, which engineers self-delivering RNAi compounds designed to silence genes that enable tumors to evade the body’s immune system. This innovative approach seeks to enhance the immune response in cancerous environments and is adaptable for both intratumoral and adoptive cell therapy applications. Among its pipeline candidates, PH-762 is an INTASYL compound engineered to diminish the expression of the PD-1 checkpoint protein, thereby activating immune cells to identify and eliminate cancer cells. This compound is currently undergoing Phase 1b clinical trials for various cutaneous malignancies, including advanced squamous cell carcinoma, melanoma, and Merkel cell carcinoma, and has recently shown encouraging safety and efficacy results in these studies. PH-762 is also being explored in conjunction with AgonOx Inc.'s "double positive" tumor-infiltrating lymphocyte technology to improve T cell-based cancer immunotherapies. Another key program, PH-894, targets the epigenetic protein BRD4 to influence gene expression in both immune and tumor cells, aiming to bolster the effectiveness of adoptive cell therapies. Additionally, PH-804 is under development to target the TIGIT immune receptor, enhancing the function of T cells and natural killer cells. The company is also investigating other INTASYL compounds, including one targeting CTLA-4, and has expanded its focus to include potential cosmeceutical applications through an exploratory collaboration. Phio Pharmaceuticals Corp. was originally established in 2011 as RXi Pharmaceuticals Corporation, later adopting its current name in November 2018 to reflect its dedicated pursuit of immuno-oncology treatments. The company maintains its headquarters in Marlborough, Massachusetts.
Company News
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
Phio Pharmaceuticals Highlights 85% Response Rate as PH-762 Nears Phase 2b
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026